CARMAT Continues to Build on Its Momentum in the EFICAS Study and Reiterates Confidence in Its 2024 Outlook

EFICAS study reaches the milestone of 20 implants



Interim study results above expectations



Confirmation of short-term financial support from several key shareholders


...

Related Keywords

France ,Paris ,France General ,Rennes ,Bretagne ,United States ,Villacoublay ,Bois Darcy ,Bourgogne ,French ,Georges Pompidou ,Linkedin ,European Union ,Food Drug Administration ,Regulatory News ,Chief Executive Officer ,French Medtech ,Early Feasibility Study ,Euronext Growth ,Des March ,Drug Administration ,Hospices Civils De Lyon ,Markets ,